Stockreport

Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? [Yahoo! Finance]

Oculis Holding AG  (OCS) 
PDF studied over 52 weeks as a potential first non-invasive treatment for diabetic macular edema, with topline data now expected in June 2026 and a possible NDA filing later [Read more]